Welcome to our dedicated page for iTeos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on iTeos Therapeutics stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) is a clinical-stage biopharmaceutical company committed to enhancing the lives of cancer patients through innovative immunotherapies. Founded in 2012 and headquartered in Gosselies, Belgium, with a research center in Watertown, Massachusetts, iTeos leverages deep insights into tumor immunology and immunosuppressive pathways to design novel product candidates.
The company's pipeline includes several promising drug candidates:
- EOS-200271: A potent and selective IDO1 inhibitor with exceptional brain penetration, currently in clinical stages.
- EOS-100850 (Inupadenant): An insurmountable adenosine A2A receptor antagonist designed to inhibit the ATP-adenosine pathway. This therapeutic candidate is in Phase 2 studies, targeting high adenosine concentrations in solid tumors.
- EOS-884448 (Belrestotug): An anti-TIGIT antibody developed to enhance the anti-tumor immune response. This candidate is being progressed in multiple indications in collaboration with GSK and is currently in Phase 1 trials.
- EOS-984: A first-in-class small molecule aimed at inhibiting the immunosuppressive activity of adenosine. This candidate is in Phase 1 development, with studies showing potential synergy with Inupadenant.
iTeos is supported by the Ludwig Institute for Cancer Research, the Walloon Region of Belgium, and the European Fund for Economic and Regional Development (FEDER). Notably, the company has secured a partnership with GSK to develop the TIGIT:PD-1 doublet therapy, which has the potential to become a leading treatment in the immuno-oncology field.
For the latest updates and detailed information, visit the 'Investors' section of their website at www.iteostherapeutics.com.
iTeos Therapeutics (ITOS) has outlined its strategic priorities for 2025, highlighting multiple clinical data readouts for its TIGIT program. The company anticipates data from over 400 patients across three trials testing belrestotug + dostarlimab in lung and head & neck cancers. Key developments include Phase 2 data readouts in 2Q25 for NSCLC and throughout 2025 for HNSCC.
The company is advancing EOS-984, with Phase 1 data expected in 2H25, and plans to submit an IND for EOS-215, a potential best-in-class anti-TREM2 antibody, in 1Q25. iTeos maintains a strong financial position with $683.9 million in cash as of September 30, 2024, providing runway through 2027.
The GALAXIES Lung-301 Phase 3 trial has received FDA and NMPA clearance, while the Lung-201 study will report interim data including safety, ORR, and ctDNA data from over 240 patients in 2Q25.
iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Michel Detheux, Ph.D., will deliver a presentation on Wednesday, January 15, 2025, at 7:30 AM PST (10:30 AM EST) in San Francisco.
Interested parties can access a live webcast of the presentation through the Investors section of iTeos's website at www.iteostherapeutics.com. The presentation recording will remain available for approximately 30 days after the event.
iTeos Therapeutics (ITOS) presented interim data from Phase 2 A2A-005 trial of inupadenant combined with carboplatin/pemetrexed in non-small cell lung cancer patients. The trial showed a 63.9% overall response rate and 7.7 months median progression-free survival across all cohorts. The recommended Phase 2 dose of 80mg demonstrated particularly strong results with a 73.3% response rate.
Despite encouraging initial signals, iTeos has decided to deprioritize inupadenant to focus resources on other programs, as the clinical activity did not meet sufficient levels for further investment. The safety profile was manageable with no dose-dependent toxicity observed.
iTeos Therapeutics (Nasdaq: ITOS) has announced its participation in two major investor conferences in December 2024. The company will attend the 7th Annual Evercore HealthCONx Conference on December 3 in Coral Gables, FL, featuring a fireside chat at 9:35 AM ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4 in New York, NY, with a fireside chat scheduled for 11:30 AM ET.
Both events will include one-on-one investor meetings. The presentations will be available via live webcast on iTeos' website, with recordings accessible for approximately 30 days afterward.
iTeos Therapeutics (ITOS) reported Q3 2024 financial results and business updates. The company received EMA clearance for belrestotug 400mg + dostarlimab as Phase 3 dose for GALAXIES Lung-301 clinical sites in EU. Pro forma cash position stood at $683.9M as of September 30, 2024, expected to provide runway through 2027. Q3 R&D expenses increased to $36.7M from $30.6M year-over-year, while G&A expenses decreased to $12.1M from $12.6M. Net loss widened to $45.4M ($1.05 per share) compared to $32.2M ($0.90 per share) in Q3 2023.
iTeos Therapeutics (ITOS) announced upcoming presentations of preclinical, translational, and clinical data for inupadenant at the ESMO Immuno-Oncology Congress 2024 in Geneva. The presentations will include results from the Phase 2 A2A-005 trial studying inupadenant combined with platinum-doublet chemotherapy in post-immunotherapy metastatic non-small cell lung cancer (NSCLC) patients. The data will be presented through two mini oral presentations and one poster session on December 12, 2024, focusing on inupadenant's effects on humoral responses and its combination with chemotherapy in NSCLC patients.
iTeos Therapeutics announced promising interim data from the GALAXIES Lung-201 Phase 2 study, evaluating belrestotug + dostarlimab in first-line, PD-L1 high non-small cell lung cancer (NSCLC) patients. Key findings include:
1. Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed across all doses
2. Confirmed ORR (cORR) of ~60% for every dose, showing a >30% difference compared to dostarlimab monotherapy
3. Safety profile consistent with known checkpoint inhibitor combinations
The company believes these results support the potential differentiation of their TIGIT:PD-1 doublet and the ongoing GALAXIES Lung-301 Phase 3 registration study.
iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical company focused on immuno-oncology therapeutics, has announced its participation in two upcoming investor conferences in September 2024. The company will be present at the Wells Fargo Healthcare Conference on September 4 in Boston, and the Cantor Fitzgerald Global Healthcare Conference on September 18 in New York.
At both events, iTeos management will engage in fireside chats and one-on-one investor meetings. The Wells Fargo conference presentation is scheduled for 4:30 PM ET, while the Cantor Fitzgerald conference presentation will take place at 10:20 AM ET. Interested parties can access live webcasts of the presentations through the Investors section of iTeos' website, with archived replays available for approximately 30 days post-event.
iTeos Therapeutics (Nasdaq: ITOS) announced that interim data from the Phase 2 GALAXIES Lung-201 study will be presented at the European Society for Medical Oncology (ESMO) Congress 2024. The study, sponsored by iTeos' partner GSK, assesses the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer. The presentation, titled 'Interim Analysis of GALAXIES Lung-201,' is scheduled for September 14, 2024, at 8:30 am CEST as a late-breaking oral presentation. This Phase 2 randomized, open-label platform study focuses on patients with PD-L1 high (TPS ≥50%) NSCLC. The abstract will be published on the ESMO website at 00:05 am CEST on the day of the presentation.
iTeos Therapeutics (Nasdaq: ITOS) reported Q2 2024 financial results and provided business updates. Key highlights include:
- Multiple clinical milestones expected in H2 2024, including two Phase 2 trials of belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC
- Pro forma cash and investments of $714.4 million as of June 30, 2024, expected to provide runway through 2027
- Q2 2024 R&D expenses increased to $36.7 million from $29.2 million in Q2 2023
- Q2 2024 net loss of $7.1 million ($0.18 per share) compared to $34.3 million ($0.96 per share) in Q2 2023
The company is advancing multiple clinical programs, including belrestotug for NSCLC and HNSCC, and adenosine pathway inhibitors inupadenant and EOS-984.
FAQ
What is the current stock price of iTeos Therapeutics (ITOS)?
What is the market cap of iTeos Therapeutics (ITOS)?
What does iTeos Therapeutics, Inc. do?
What are the key products in iTeos' pipeline?
Where is iTeos Therapeutics headquartered?
What is EOS-200271?
What is Inupadenant (EOS-100850)?
Who are iTeos' key partners?
What is EOS-884448 (Belrestotug)?
What is EOS-984?
Where can I find the latest news about iTeos Therapeutics?
